Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLPROPION HYDROCHLORIDE versus LOMAIRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLPROPION HYDROCHLORIDE versus LOMAIRA.
DIETHYLPROPION HYDROCHLORIDE vs LOMAIRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sympathomimetic amine with anorectic activity; stimulates release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to appetite suppression.
Lomitapide inhibits microsomal triglyceride transfer protein (MTP), which is responsible for the assembly and secretion of apolipoprotein B-containing lipoproteins in the liver and intestine, thereby reducing plasma levels of LDL-C, triglycerides, and other lipids.
25 mg orally three times daily, 1 hour before meals; extended-release: 75 mg orally once daily in midmorning.
100 mg orally once daily, with or without food.
None Documented
None Documented
4-6 hours (parent drug); clinical effects correlate with plasma levels, requiring multiple daily dosing.
Terminal elimination half-life: 12 hours; clinical context: steady-state achieved in 2-3 days.
Approximately 70-80% of the dose is excreted renally as metabolites; less than 10% as unchanged drug. Biliary/fecal excretion accounts for the remainder.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other.
Category C
Category C
Appetite Suppressant
Appetite Suppressant